Collection: Sollagen

Cellular therapy for the support of Diabetic Foot Ulcers.

CellResearch Corporation: A leader in cellular therapy for the treatment of diabetic skin.

CellResearchCorp is a biotech company that utilizes a unique cellular technology platform derived from the umbilical cord lining. It has established a group of companies to manage the various businesses related to cord lining technology. These include a USFDA-trialed wound-healing drug, a diabetic skincare system, a cosmeceutical range and cord banking licensing.

CellResearchCorp had made the discovery that the cord lining is a rich source of MSCs and EpSCs. This novel and significant discovery is patent protected in multiple strategic key territories around the world. CellResearchCorp also has a broad therapeutic pipeline at the pre-clinical stage which utilizes cord lining technology; these include solid tumor therapy, treatment of inflammatory diseases, Parkinson’s Diseases, Age-related Macular Degeneration, Diabetes and cardiac muscle repair.

CellResearchCorp’s first allogeneic therapy completes Phase 1 USFDA clinical trials for the treatment of diabetic foot ulcers with its product, CorLiCyte®

CorLiCyte® is a physician-applied therapy for chronic diabetic wounds that utilizes cord lining MSCs. Its indication is treatment of DFU in advanced stages.

PTT-6® the active ingredient of Sollagen™, is developed from media derived from cord lining and contains over 3,000 proteins, including Growth Factors and Cytokines.

CellResearchCorp for diabetic skin: Providing integrated DFU support for all stages.